Dendritic Cells-Derived Exosomes in Human Sepsis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02957279|
Recruitment Status : Unknown
Verified November 2016 by Jianan Ren, Jinling Hospital, China.
Recruitment status was: Recruiting
First Posted : November 6, 2016
Last Update Posted : November 6, 2016
|Condition or disease||Intervention/treatment|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||A Cohort Study to Investigate the Impacts of Peripheral Blood Dendritic Cells-Derived Exosomes at Early Phase on the Prognosis in Human Sepsis|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||September 2017|
|Estimated Study Completion Date :||October 2017|
The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
In the sepsis group, antibiotics were used when needed.
Healthy control group
- Amount of dendritic cell-derived exosomes [ Time Frame: The first 4 hour after admission ]
- Compositions of microRNA in the dendritic cell-derived exosomes [ Time Frame: The first 4 hour after admission ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02957279
|Contact: Jianan Ren, MDfirstname.lastname@example.org|
|Contact: Yuan Li, MDemail@example.com|
|Principal Investigator:||Jianan Ren, MD||Jinling Hospital, Medical School of Nanjing University|